2024-07-01 19:58:33
Valneva General Manager Thomas Lingelbach at Valneva Laboratories’ Livingston (Scotland) facility on March 28, 2022.
On Friday, June 28, the European Commission approved the marketing in the Old Continent of the Ixchiq vaccine developed by the French-Austrian pharmaceutical laboratory Valneva. It is the world’s first and so far only vaccine designed to prevent chikungunya infection.
This viral disease is transmitted to humans through the bite of an infected mosquito, specifically through Aedes albopictusThe mosquito, better known as the tiger mosquito, is now found primarily in the Southern Hemisphere. However, under the influence of global warming, the emergence of tiger mosquitoes in Europe and their rapid spread across the continent in recent years poses a threat.
On June 11, the European Center for Disease Prevention and Control, the European Union’s public health agency responsible for collecting and analyzing infectious disease data, responded to this. « Aedes albopictusThe viruses known to transmit dengue, chikungunya and Zika are spreading further north, east and west across Europe and now have self-sustaining populations in 13 countries. [l’UE] and the European Economic Area »he pointed out.
READ ALSO | Article reserved for our subscribers Valneva laboratory is trying to reboot itself with its vaccine once morest chikungunya
Add to your selection
In most cases, chikungunya causes high fever and debilitating joint pain that can last for months. But the virus can also be fatal to the most severely affected patients.
Covid-19 vaccine commercial failure
Therefore, with this approval, Brussels is strengthening the treatments available in the twenty-seven countries to prevent future epidemics. “Infected mosquitoes pose a potentially dangerous new challenge to public health, and we are committed to using every tool at our disposal to address these risks and protect our citizens. »Stella Kyriakides, EU Commissioner for Health and Consumer Policy commented.
The vaccine, developed by the French-Austrian laboratory Valneva, based in Saint-Herblain (Loire-Atlantique) near Nantes (Loire-Atlantique), is so far only available to adults over 18 and is partly financially supported by Alliance for Epidemic Preparedness Innovations, an organization supported by private and public funding.
Also read: Covid-19: European Medicines Agency authorizes Valneva vaccine
Add to your selection
Following the announcement of European authorization in Canada on June 24 and the United States in November 2023, this should restore color to the company, which has been hammered by investors since the commercial failure of its Covid-19 vaccine. Especially at the moment, the laboratory has no competitors in this market, which, according to the laboratory, has annual sales of approximately $500 million (€465 million).
There are 35.46% left to read in this article. The remainder is reserved for subscribers.
1720656893
#Valneva #approval #sell #chikungunya #vaccine
